Automatic speaker diarization for natural conversation analysis in autism clinical trials.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 06 2023
Historique:
received: 07 12 2022
accepted: 08 06 2023
medline: 26 6 2023
pubmed: 25 6 2023
entrez: 24 6 2023
Statut: epublish

Résumé

Challenges in social communication is one of the core symptom domains in autism spectrum disorder (ASD). Novel therapies are under development to help individuals with these challenges, however the ability to show a benefit is dependent on a sensitive and reliable measure of treatment effect. Currently, measuring these deficits requires the use of time-consuming and subjective techniques. Objective measures extracted from natural conversations could be more ecologically relevant, and administered more frequently-perhaps giving them added sensitivity to change. While several studies have used automated analysis methods to study autistic speech, they require manual transcriptions. In order to bypass this time-consuming process, an automated speaker diarization algorithm must first be applied. In this paper, we are testing whether a speaker diarization algorithm can be applied to natural conversations between autistic individuals and their conversational partner in a natural setting at home over the course of a clinical trial. We calculated the average duration that a participant would speak for within their turn. We found a significant correlation between this feature and the Vineland Adaptive Behaviour Scales (VABS) expressive communication score (r = 0.51, p = 7 × 10

Identifiants

pubmed: 37355730
doi: 10.1038/s41598-023-36701-4
pii: 10.1038/s41598-023-36701-4
pmc: PMC10290724
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10270

Subventions

Organisme : NIDCD NIH HHS
ID : R01 DC014279
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

PLoS One. 2017 Mar 15;12(3):e0173936
pubmed: 28296973
Sci Transl Med. 2016 Jan 13;8(321):321fs1
pubmed: 26764154
Autism Res. 2022 Jun;15(6):1090-1108
pubmed: 35199482
J Speech Lang Hear Res. 2014 Aug;57(4):1162-77
pubmed: 24686340
J Autism Dev Disord. 2019 Oct;49(10):4294-4305
pubmed: 31338717
Autism Res. 2017 Mar;10(3):384-407
pubmed: 27501063
Mol Autism. 2020 Aug 26;11(1):66
pubmed: 32847616
Autism. 2015 Jul;19(5):622-36
pubmed: 25096930
Autism. 2012 May;16(3):306-20
pubmed: 21705474
Autism Res. 2013 Oct;6(5):372-83
pubmed: 23661504
Appl Neuropsychol Adult. 2014;21(1):51-9
pubmed: 24826496
J Neurodev Disord. 2020 Mar 24;12(1):10
pubmed: 32204695
J Child Adolesc Psychopharmacol. 2017 Nov;27(9):814-822
pubmed: 28498053
Sci Rep. 2021 May 26;11(1):10968
pubmed: 34040042
Comput Speech Lang. 2016 May;37:47-66
pubmed: 28713198

Auteurs

James O'Sullivan (J)

Roche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.

Guy Bogaarts (G)

Roche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.

Philipp Schoenenberger (P)

Neuroscience Early Development, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.

Julian Tillmann (J)

Neuroscience Early Development, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.

David Slater (D)

Roche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.

Nima Mesgarani (N)

Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, 10027, USA.

Eckhart Eule (E)

Neuroscience Early Development, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.

Timothy Kilchenmann (T)

Roche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.

Lorraine Murtagh (L)

Neuroscience & Rare Diseases, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.

Joerg Hipp (J)

Neuroscience & Rare Diseases, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.

Michael Lindemann (M)

Roche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.

Florian Lipsmeier (F)

Roche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland. florian.lipsmeier@roche.com.

Wei-Yi Cheng (WY)

Roche Innovation Center New York, Roche TCRC Inc., New York, USA.

David Nobbs (D)

Roche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.

Christopher Chatham (C)

Biomarkers & Translational Technology, Neuroscience & Rare Diseases, Pharma Research & Early Development, Roche Innovation Center New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH